COVID-19: Report casts doubts on UBI vaccine’s efficacyStaff writer, with CNAA report by experts released by the Food and Drug Administration (FDA) on Monday raised doubts as to whether the vaccine developed by United Biomedical Inc (UBI) Asia offers sufficient protection against COVID-19 variants. UBI has said that its vaccine candidate is expected to protect those inoculated against the Delta variant of SARS-CoV-2, which is now the most transmittable and contagious variant worldwide. The report also cited some experts on the panel as saying that UBI’s vaccine did not even appear to be effective against the original SARS-CoV-2 virus. Despite its application being rejected in Taiwan, UBI remains committed to seeking international approval for its COVID-19 vaccine candidate, Wang said. The company plans to conduct phase 3 clinical trials in India for its “next generation” COVID-19 vaccine, named “UB-613,” she said.

Source: Taipei Times September 01, 2021 15:56 UTC